A randomized, double‐blind, placebo‐controlled, dose‐finding trial with Lolium perenne peptide immunotherapy

por Mösges, R., Kasche, E. M., Raskopf, E., Singh, J., Sohlich, L., Astvatsatourov, A., Shah‐Hosseini, K., Pirotton, S., Haazen, L., Durham, S. R., Legon, T., Zadoyan, G., Shamji, M. H.
Publicado 2017

Lolium perenne peptide immunotherapy is well tolerated and elicits a protective B‐cell response in seasonal allergic rhinitis patients

por Mösges, R., Koch, A. F., Raskopf, E., Singh, J., Shah‐Hosseini, K., Astvatsatourov, A., Hauswald, B., Yarin, Y., Corazza, F., Haazen, L., Pirotton, S., Allekotte, S., Zadoyan, G., Legon, T., Durham, S. R., Shamji, M. H.
Publicado 2018